Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01801436 · OUTCOME

Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma · Source last updated 2013-05-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Liter per Hour
Interval / dispersion
Standard Deviation
Time frame
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

What was measured

Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).

Analysis population: The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.

Groups in this outcome

Bortezomib

Participants received 1.3 mg per m\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib10

Reported measurements

Source class 1
Values in Liter per Hour · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bortezomib4.682.46Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        2.46
        value
        4.68
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).
dispersion Type
Standard Deviation
groups
  1. description
    Participants received 1.3 mg per m\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
    id
    OG000
    title
    Bortezomib
param Type
MEAN
population Description
The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.
reporting Status
POSTED
time Frame
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
title
Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1
type
PRIMARY
unit Of Measure
Liter per Hour

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice